These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3093154)

  • 1. In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Meyer RD; Liu S
    Chemotherapy; 1986; 32(5):425-30. PubMed ID: 3093154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
    Smith BR; LeFrock JL; Donato JB; Joseph WS; Weber SJ
    Antimicrob Agents Chemother; 1986 Feb; 29(2):355-8. PubMed ID: 3717937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA; Nathan C; Delzell D; Kabins SA
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of Ro 23-6240, a new fluorinated 4-quinolone.
    Stobberingh EE; Houben AW; van Boven CP
    Chemotherapy; 1987; 33(3):197-203. PubMed ID: 3109817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa.
    Meyer RD; Liu S
    Diagn Microbiol Infect Dis; 1988 Nov; 11(3):151-7. PubMed ID: 3149927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Aug; 6(4):482-5. PubMed ID: 3117538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
    DiVincenzo CA; Shatzer KL; Venezio FR
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):13S-16S. PubMed ID: 2507220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
    Tumah H
    Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem].
    Pascual A A; Joyanes P; Martínez-Martínez L; del Carmen Conejo M; Hernández G; Chaves J; Perea EJ
    Enferm Infecc Microbiol Clin; 2001 Nov; 19(9):432-4. PubMed ID: 11709121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.
    Fass RJ
    Antimicrob Agents Chemother; 1982 Jun; 21(6):1003-6. PubMed ID: 6810755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
    Kanellakopoulou K; Sarafis P; Galani I; Giamarellou H; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative activities of three new antibacterial agents with aztreonam against gram-negative bacilli.
    Kafetzis DA; Legakis NJ
    Chemioterapia; 1987 Jun; 6(2 Suppl):110-2. PubMed ID: 3151330
    [No Abstract]   [Full Text] [Related]  

  • 20. [In vitro effect of various antibiotics: beta lactams, aminoglycosides and fluoroquinolones alone and in combination against P. aeruginosa isolated from patients with mucoviscidosis].
    Croize J; Gout JP; Robert J; Le Noc P
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):573-7. PubMed ID: 2508041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.